1-Pyrimidinylpiperazine (BioDeep_00000018340)

   

human metabolite Endogenous blood metabolite Chemicals and Drugs


代谢物信息卡片


1-(2-PYRIMIDINYL) PIPERAZINE

化学式: C8H12N4 (164.10619119999998)
中文名称: 1-(2-嘧啶基)哌嗪
谱图信息: 最多检出来源 Homo sapiens(blood) 3.23%

分子结构信息

SMILES: C1CN(CCN1)C1=NC=CC=N1
InChI: InChI=1S/C8H12N4/c1-2-10-8(11-3-1)12-6-4-9-5-7-12/h1-3,9H,4-7H2

描述信息

1-Pyrimidinylpiperazine is a metabolite of buspirone. Buspirone is an anxiolytic psychoactive drug of the azapirone chemical class, and is primarily used to treat generalized anxiety disorder (GAD) Bristol-Myers Squibb (BMS) gained FDA approval of buspirone in 1986 for treatment of GAD. The patent on Buspar by Bristol-Myers Squibb expired in 2001, and buspirone is available as a generic. (Wikipedia)
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents
D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents
D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants

同义名列表

6 个代谢物同义名

1-(2-PYRIMIDINYL) PIPERAZINE; 2-(piperazin-1-yl)pyrimidine; 2-(1-Piperazinyl)pyrimidine; 1-(2-Pyrimidinyl)piperazine; 1-Pyrimidinylpiperazine; pyrimidinylpiperazine



数据库引用编号

8 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Wenya Hu, Mi Jia, Siyan He, Huiru Xie, Xuehua Jiang, Ling Wang. Simultaneous determination of tandospirone and its active metabolite, 1-[2-pyrimidyl]-piperazine in rat plasma by LC-MS/MS and its application to a pharmacokinetic study. Biomedical chromatography : BMC. 2019 Jul; 33(7):e4525. doi: 10.1002/bmc.4525. [PMID: 30822365]
  • Lijun Zhu, Linlin Lu, Enshuang Guo, Jinjun Wu, Ying Wang, Ming Hu, Zhongqiu Liu. The influences of aconitine, an active/toxic alkaloid from aconitum, on the oral pharmacokinetics of CYP3A probe drug buspirone in rats. Drug metabolism letters. 2014; 8(2):135-44. doi: 10.2174/1872312808666140505162139. [PMID: 25434398]
  • Lijun Zhu, Xiaoshan Yang, Juan Zhou, Lan Tang, Bijun Xia, Ming Hu, Fuyuan Zhou, Zhongqiu Liu. The exposure of highly toxic aconitine does not significantly impact the activity and expression of cytochrome P450 3A in rats determined by a novel ultra performance liquid chromatography-tandem mass spectrometric method of a specific probe buspirone. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association. 2013 Jan; 51(?):396-403. doi: 10.1016/j.fct.2012.10.008. [PMID: 23085095]
  • Raman Sharma, Hao Sun, David W Piotrowski, Tim F Ryder, Shawn D Doran, Haiqing Dai, Chandra Prakash. Metabolism, excretion, and pharmacokinetics of ((3,3-difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone, a dipeptidyl peptidase inhibitor, in rat, dog and human. Drug metabolism and disposition: the biological fate of chemicals. 2012 Nov; 40(11):2143-61. doi: 10.1124/dmd.112.047316. [PMID: 22896728]
  • Parul Gor, Yazen Alnouti, Gregory A Reed. Buspirone, fexofenadine, and omeprazole: quantification of probe drugs and their metabolites in human plasma. Journal of pharmaceutical and biomedical analysis. 2011 Jul; 55(5):1127-35. doi: 10.1016/j.jpba.2011.03.043. [PMID: 21546194]
  • Xiaoqiang Qiao, Liangliang Sun, Lingfan Chen, Yuan Zhou, Kaiguang Yang, Zhen Liang, Lihua Zhang, Yukui Zhang. Piperazines for peptide carboxyl group derivatization: effect of derivatization reagents and properties of peptides on signal enhancement in matrix-assisted laser desorption/ionization mass spectrometry. Rapid communications in mass spectrometry : RCM. 2011 Mar; 25(5):639-46. doi: 10.1002/rcm.4903. [PMID: 21290451]
  • Hiroyuki Nishikawa, Takeshi Inoue, Takuya Masui, Takeshi Izumi, Shin Nakagawa, Tsukasa Koyama. Pharmacokinetic interaction between tandospirone and fluvoxamine in the rat contextual conditioned fear stress model and its functional consequence: Involvement of cytochrome P450 3A4. Psychiatry and clinical neurosciences. 2008 Oct; 62(5):591-6. doi: 10.1111/j.1440-1819.2008.01853.x. [PMID: 18950380]
  • Harvey Wong, Randy C Dockens, Lori Pajor, Suresh Yeola, James E Grace, Arlene D Stark, Rebecca A Taub, Frank D Yocca, Robert C Zaczek, Yu-Wen Li. 6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats. Drug metabolism and disposition: the biological fate of chemicals. 2007 Aug; 35(8):1387-92. doi: 10.1124/dmd.107.015768. [PMID: 17494642]
  • David J Edwards, Diane C Chugani, Harry T Chugani, Jamal Chehab, Monica Malian, Jacob V Aranda. Pharmacokinetics of buspirone in autistic children. Journal of clinical pharmacology. 2006 May; 46(5):508-14. doi: 10.1177/0091270006286903. [PMID: 16638734]
  • A H Vaidya, D I Rosenthal, W Lang, J J Crooke, D Benjamin, S E Ilyin, A B Reitz. Oral buspirone causes a shift in the dose-response curve between the elevated-plus maze and Vogel conflict tests in Long-Evans rats: relation of brain levels of buspirone and 1-PP to anxiolytic action. Methods and findings in experimental and clinical pharmacology. 2005 May; 27(4):245-55. doi: 10.1358/mf.2005.27.4.893584. [PMID: 16082425]
  • Yumi Sugimoto, Nozomu Takashima, Toshiko Noma, Jun Yamada. Inhibitory effects of the 5-HT(1A) receptor agonist buspirone on stress-induced hyperglycemia in mice: involvement of insulin and a buspirone metabolite, 1-(2-pyrimidinyl)piperazine (1-PP). Biological & pharmaceutical bulletin. 2005 Apr; 28(4):733-5. doi: 10.1248/bpb.28.733. [PMID: 15802819]
  • Yumi Sugimoto, Nozomu Takashima, Toshiko Noma, Jun Yamada. Effects of the serotonergic anxiolytic buspirone on plasma glucose and glucose-induced hyperglycemia in mice. Journal of pharmacological sciences. 2003 Dec; 93(4):446-50. doi: 10.1254/jphs.93.446. [PMID: 14737015]
  • Kari Laine, Outi Ahokoski, Risto Huupponen, Jutta Hänninen, Sanna Palovaara, Jori Ruuskanen, Harry Björklund, Markku Anttila, Juha Rouru. Effect of the novel anxiolytic drug deramciclane on the pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug buspirone. European journal of clinical pharmacology. 2003 Dec; 59(10):761-6. doi: 10.1007/s00228-003-0674-3. [PMID: 14566442]
  • C J Timmer, J M A Sitsen. Pharmacokinetic evaluation of gepirone immediate-release capsules and gepirone extended-release tablets in healthy volunteers. Journal of pharmaceutical sciences. 2003 Sep; 92(9):1773-8. doi: 10.1002/jps.10421. [PMID: 12949996]
  • D E Salazar, E J Frackiewicz, R Dockens, G Kollia, I E Fulmor, P D Tigel, H D Uderman, T M Shiovitz, J J Sramek, N R Cutler. Pharmacokinetics and tolerability of buspirone during oral administration to children and adolescents with anxiety disorder and normal healthy adults. Journal of clinical pharmacology. 2001 Dec; 41(12):1351-8. doi: 10.1177/00912700122012823. [PMID: 11762563]
  • A Sakr, M Andheria. A comparative multidose pharmacokinetic study of buspirone extended-release tablets with a reference immediate-release product. Journal of clinical pharmacology. 2001 Aug; 41(8):886-94. doi: 10.1177/00912700122010681. [PMID: 11504277]
  • A Sakr, M Andheria. Pharmacokinetics of buspirone extended-release tablets: a single-dose study. Journal of clinical pharmacology. 2001 Jul; 41(7):783-9. doi: 10.1177/00912700122010582. [PMID: 11452712]
  • K T Kivistö, J Laitila, K Mårtensson, P J Neuvonen. Determination of buspirone and 1-(2-pyrimidinyl)-piperazine (1-PP) in human plasma by capillary gas chromatography. Therapeutic drug monitoring. 1999 Jun; 21(3):317-21. doi: 10.1097/00007691-199906000-00011. [PMID: 10365644]
  • P H Marathe, F Shen, P Markham, D S Greene. Pharmacokinetics of buspirone following oral administration to rhesus monkeys. The Journal of pharmacy and pharmacology. 1999 May; 51(5):601-7. doi: 10.1211/0022357991772709. [PMID: 10411220]
  • I Mahmood, C Sahajwalla. Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. Clinical pharmacokinetics. 1999 Apr; 36(4):277-87. doi: 10.2165/00003088-199936040-00003. [PMID: 10320950]
  • K T Kivistö, T S Lamberg, P J Neuvonen. Interactions of buspirone with itraconazole and rifampicin: effects on the pharmacokinetics of the active 1-(2-pyrimidinyl)-piperazine metabolite of buspirone. Pharmacology & toxicology. 1999 Feb; 84(2):94-7. doi: 10.1111/j.1600-0773.1999.tb00880.x. [PMID: 10068153]
  • V Jagannathan, J Venitz. Pharmacokinetics and CNS pharmacodynamics of the 5-HT1A agonist buspirone in humans following acute L-tryptophan depletion challenge. Methods and findings in experimental and clinical pharmacology. 1997 Jun; 19(5):351-62. doi: NULL. [PMID: 9379784]
  • J Odontiadis, M Franklin. Simultaneous quantitation of buspirone and its major metabolite 1-(2-pyrimidinyl)piperazine in human plasma by high-performance liquid chromatography with coulometric detection. Journal of pharmaceutical and biomedical analysis. 1996 Jan; 14(3):347-51. doi: 10.1016/0731-7085(95)01606-6. [PMID: 8851759]
  • I Berlin, S Chalon, C Payan, G Schöllnhammer, F Cesselin, O Varoquaux, A J Puech. Evaluation of the alpha 2-adrenoceptor blocking properties of buspirone and ipsapirone in healthy subjects. Relationship with the plasma concentration of the common metabolite 1-(2-pyrimidinyl)-piperazine. British journal of clinical pharmacology. 1995 Mar; 39(3):243-9. doi: 10.1111/j.1365-2125.1995.tb04443.x. [PMID: 7619663]
  • S M Evans, J R Troisi, R R Griffiths. Tandospirone and alprazolam: comparison of behavioral effects and abuse liability in humans. The Journal of pharmacology and experimental therapeutics. 1994 Nov; 271(2):683-94. doi: NULL. [PMID: 7965783]
  • S E Mulroney, C Skudlarek, A Shemer, M D Lumpkin, K J Kellar. Tandospirone stimulates prolactin secretion in the rat by an action at serotonin-1A receptors. The Journal of pharmacology and experimental therapeutics. 1994 Feb; 268(2):862-7. doi: NULL. [PMID: 8113999]
  • R H Barbhaiya, U A Shukla, M Pfeffer, K A Pittman, R Shrotriya, C Laroudie, R E Gammans. Disposition kinetics of buspirone in patients with renal or hepatic impairment after administration of single and multiple doses. European journal of clinical pharmacology. 1994; 46(1):41-7. doi: 10.1007/bf00195914. [PMID: 7911763]
  • L K Tay, M A Sciacca, M B Sostrin, R H Farmen, K A Pittman. Effect of food on the bioavailability of gepirone in humans. Journal of clinical pharmacology. 1993 Jul; 33(7):631-5. doi: 10.1002/j.1552-4604.1993.tb04715.x. [PMID: 8103528]
  • L G Miller, M L Thompson, J J Byrnes, D J Greenblatt, A Shemer. Kinetics, brain uptake, and receptor binding of tandospirone and its metabolite 1-(2-pyrimidinyl)-piperazine. Journal of clinical psychopharmacology. 1992 Oct; 12(5):341-5. doi: NULL. [PMID: 1362206]
  • P Betto, A Meneguz, G Ricciarello, S Pichini. Simultaneous high-performance liquid chromatographic analysis of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in plasma using electrochemical detection. Journal of chromatography. 1992 Mar; 575(1):117-21. doi: 10.1016/0378-4347(92)80511-n. [PMID: 1355487]
  • A Diaz-Marot, E Puigdellivol, C Salvatella, L Comellas, M Gassiot. Determination of buspirone and 1-(2-pyrimidinyl)piperazine in plasma samples by high-performance liquid chromatography. Journal of chromatography. 1989 May; 490(2):470-3. doi: 10.1016/s0378-4347(00)82808-x. [PMID: 2768419]
  • G K Matheson, D Gage-White, G White, D Guthrie, J Rhoades, V Dixon. The effects of gepirone and 1-(2-pyrimidinyl)-piperazine on levels of corticosterone in rat plasma. Neuropharmacology. 1989 Apr; 28(4):329-34. doi: 10.1016/0028-3908(89)90026-9. [PMID: 2747846]
  • G Bianchi, S Caccia. Simultaneous determination of buspirone, gepirone, ipsapirone and their common metabolite 1-(2-pyrimidinyl)piperazine in rat plasma and brain by high-performance liquid chromatography. Journal of chromatography. 1988 Oct; 431(2):477-80. doi: 10.1016/s0378-4347(00)83123-0. [PMID: 2907515]
  • M A Sciacca, G F Duncan, J P Shea, H C Faulkner, R H Farmen, K A Pittman. Simultaneous quantitation of buspirone and 1-(2-pyrimidinyl)piperazine in human plasma and urine by capillary gas chromatography-mass spectrometry. Journal of chromatography. 1988 Jul; 428(2):265-74. doi: 10.1016/s0378-4347(00)83917-1. [PMID: 3215930]
  • G Bianchi, S Caccia, F Della Vedova, S Garattini. The alpha 2-adrenoceptor antagonist activity of ipsapirone and gepirone is mediated by their common metabolite 1-(2-pyrimidinyl)-piperazine (PmP). European journal of pharmacology. 1988 Jul; 151(3):365-71. doi: 10.1016/0014-2999(88)90532-8. [PMID: 2905658]
  • S Caccia, G L Vigano, G Mingardi, S Garattini, R E Gammans, M Placchi, R F Mayol, M Pfeffer. Clinical pharmacokinetics of oral buspirone in patients with impaired renal function. Clinical pharmacokinetics. 1988 Mar; 14(3):171-7. doi: 10.2165/00003088-198814030-00005. [PMID: 3370902]
  • R E Gammans, M Pfeffer, M L Westrick, H C Faulkner, K D Rehm, P J Goodson. Lack of interaction between cimetidine and buspirone. Pharmacotherapy. 1987; 7(3):72-9. doi: 10.1002/j.1875-9114.1987.tb03521.x. [PMID: 2888096]
  • E H Kerns, W W Bullen, R E Gammans. Quantitative analysis of 1-(2-pyrimidinyl)piperazine in plasma by capillary gas chromatography-mass spectrometry. Journal of chromatography. 1986 Apr; 377(?):195-203. doi: 10.1016/s0378-4347(00)80774-4. [PMID: 3711208]
  • S Caccia, I Conti, G Viganò, S Garattini. 1-(2-Pyrimidinyl)-piperazine as active metabolite of buspirone in man and rat. Pharmacology. 1986; 33(1):46-51. doi: 10.1159/000138199. [PMID: 2874572]
  • S Caccia, M Muglia, A Mancinelli, S Garattini. Disposition and metabolism of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in the rat. Xenobiotica; the fate of foreign compounds in biological systems. 1983 Mar; 13(3):147-53. doi: 10.3109/00498258309052248. [PMID: 6613160]
  • S Caccia, S Garattini, A Mancinelli, M Muglia. Identification and quantitation of 1-(2-pyrimidinyl)piperazine, an active metabolite of the anxiolytic agent buspirone, in rat plasma and brain. Journal of chromatography. 1982 Dec; 252(?):310-4. doi: 10.1016/s0021-9673(01)88424-7. [PMID: 7182413]